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Abstract
Background: The metastatic cascade is a complex and multistep process with many potential barriers. Recently,
miR-193a has been reported to be a suppressive miRNA in multiple types of cancers, but its underlying anti-oncogenic
activity in non-small cell lung cancers (NSCLC) is not fully elucidated.
Methods: The expressions of miR-193a (miR-193a-5p) in human lung cancer tissues and cell lines were detected by
real-time PCR. Dual-luciferase reporter assay was used to identify the direct target of miR-193a. Cell proliferation, apoptosis,
and metastasis were assessed by CCK-8, flow cytometry, and Transwell assay, respectively.
Results: The expression of miR-193a in lung cancer tissues was decreased comparing to adjacent non-tumor
tissues due to DNA hypermethylation in lung cancer tissues. Ectopic expression of miR-193a inhibited cell
proliferation, colony formation, migration, and invasion in A549 and H1299 cells. Moreover, overexpression of
miR-193a partially reversed tumor growth factor-β1 (TGF-β1)-induced epithelial-to-mesenchymal transition
(EMT) in NSCLC cells. Mechanistically, miR-193a reduced the expression of WT1, which negatively regulated
the protein level of E-cadherin, suggesting that miR-193a might prevent EMT via modulating WT1-E-cadherin
axis. Importantly, knockdown of WT1 resembled the anti-cancer activity by miR-193a and overexpression of
WT1 partially reversed miR-193a-induced anti-cancer activity, indicating that WT1 plays an important role in
miR-193a-induced anti-cancer activity. Finally, overexpression of miR-193a decreased the growth of tumor
xenografts in mice.
Conclusion: Collectively, our results have revealed an important role of miR-193a-WT1-E-cadherin axis in
metastasis, demonstrated an important molecular cue for EMT, and suggested a therapeutic strategy of
restoring miR-193a expression in NSCLC.
Keywords: MiR-193a, Wilm’s tumor-1, E-cadherin, Epithelial-to-mesenchymal transition
* Correspondence: Wujianbo@msn.com
†Equal contributors
2Laboratory of Internal Medicine, The First Affiliated Hospital of Wenzhou
Medical University, Nanbaixiang, Ouhai District, Wenzhou, Zhejiang Province,
China
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Chen et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:173 
DOI 10.1186/s13046-016-0450-8
Background
Lung cancer is the leading cause of cancer-related deaths
in the world [1]. Although great efforts have been made
toward improving overall survival and reducing cancer-
related death including discovering of new biomarkers
[2], development of specific drugs [3], and establishment
of modified operation [4], the outcome is still poor. Me-
tastasis is the leading reason for the resultant mortality
in more than 90 % of patients with cancer, including
lung cancer. Metastasis is a complex process in which
the metastatic potential of NSCLC cells is influenced by
cell-intrinsic identities and extrinsic microenvironment
factors. Metastasis is also associated with epithelial-
mesenchymal transition (EMT), a biologic process during
which epithelial cells acquire new features of mesenchyme
[5]. The reduction of E-cadherin, a marker of epithelial
cells, is currently thought to promote metastasis during
early carcinogenesis progression [6]. E-cadherin is inhib-
ited by many transcript factors such as Snail, ZEB1/2, and
Slug, which are induced by multiple signaling pathways
including Wnt, TGF-β, and Notch [7, 8]. For example,
TGF-β promotes tumor progression through enhancing
migration and invasion, and induces EMT through inhi-
biting the expressions of Snail and Slug [9].
Wilms tumor 1 gene (WT1) was firstly identified as a
tumor suppressor gene, encoding a 49–52 kDa protein with
four zinc fingers in C-terminal domain in nephroblastoma,
also known as Wilms tumor, a childhood tumor of the
kidney [10]. However, subsequent accumulating studies
demonstrated that high expression of WT1 was detected in
different types of solid cancers and hematological malig-
nancies, such as breast cancer [11], lung cancer [12], and
leukemia [13]. At least four major isoforms ofWT1, includ-
ing 17AA(+)KTS(+), 17AA(+)KTS(-), 17AA(-)KTS(+), and
17AA(-)KTS(-), were discovered according to two different
sites. These isoforms were expressed in primary solid
tumors and primary leukemic blasts and presented different
functions [14]. Furthermore, overexpression of WT1
enhanced proliferation through upregulation of cyclin D1
and p-pRb in NSCLC cells [12]. WT1 suppressed the
expression of E-cadherin through directly binding its pro-
moter to enhance the invasion [15]. Thus, WT1 plays an
important role in promoting proliferation and invasion in
NSCLC cells.
MicroRNAs (miRNAs) are a class of short single-
stranded noncoding RNAs with approximately 20
nucleotides in length. MiRNAs inhibit the target gene
expressions by either inhibiting translation or inducing
mRNA degradation [16]. Recently, emerging data have
shown that miRNAs were often deregulated in multiple
types of cancers and played an important role in prolifera-
tion, apoptosis, differentiation, drug resistance, and metas-
tasis [17–20]. In NSCLC, only a few miRNAs were
identified in metastasis, including miR-31 [21] and miR-
135b [22]. Thus, it is an urgent need to identify useful
miRNAs that provide as a potential new therapeutic arget.
However, whether WT1 can be regulated by miRNAs in
lung cancer cells is not fully understood.
MiR-193a was reported to be a suppressive miRNA and
overexpression of miR-193a suppressed proliferation and
promoted apoptosis via targeting several oncogenes, such
as c-KIT [23] and MCL-1 [24]. In addition, miR-193a
regulated metastasis in solid cancers including NSCLC.
For example, miR-193a inhibited invasion by negatively
regulating ERBB4/PIK3R3/mTOR/S6K2 signaling path-
way in NSCLC [25]. MiR-193a inhibited the metastasis of
lung cancer cells by deregulating the expression of tumor-
related proteins [26]. Thus, these results suggest that miR-
193a might regulate the metastasis in NSCLC. The
decrease of E-cadherin is an important procedure for the
promotion of invasion. However, whether miR-193a can
regulate E-cadherin expression is not determined. Because
WT1 is implicated in the metastasis of NSCLC through
inhibiting the expression of E-cadherin [15], we hypothe-
sized that one mechanism of anti-metastasis activity of
miR-193a might perform by modulating WT1-E-cadherin
axis.
Here, we report a miR-193a-WT1-E-cadherin axis in
NSCLC. Decreased expression of miR-193a regulated
TGF-β1-induced EMT progress. Overexpression of miR-
193a inhibited migration and invasion via modulating
WT1-E-cadherin axis. Additionally, miR-193a partially
prevented TGF-β1-induced EMT, suggesting that miR-
193a plays an important role in TGF-β1-induced EMT.
Therefore, targeting miR-193a-WT1-E-cadherin axis
might provide a novel strategy to improve survival in
lung cancer patients.
Methods
Cell lines and tissue specimens
Multiple lung cancer cell lines and normal lung epithe-
lial cell line BEAS-2B (Cell Bank of Shanghai Institutes
for Biological Sciences, Shanghai, China) were used in
this study. A549 and H1299 were cultured in RPMI
1640 medium, whereas 293T was cultured in Dulbecco’s
Modified Eagle Medium (DMEM) high-glucose medium.
All cells were supplemented with 10 % fetal bovine
serum (Invitrogen, Carlsbad, USA) and maintained in a
humidified 37 °C incubator with 5 % CO2. Total 62
paired lung cancer specimens including lung cancer and
paired adjacent normal tissues were collected from
patients undergoing surgical resection in the Depart-
ment of Thoracic Surgery, the First Affiliated Hospital of
Wenzhou Medical University. Non-tumor samples from
the macroscopic tumor margin were isolated at the same
time and used as the matched adjacent normal tissues.
Informed consents were obtained from all patients. All
the samples were divided into two parts. One part was
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immediately frozen and stored in liquid nitrogen until
RNA extraction. Another part was stored in formalin for
pathology analysis. These patients’ histological type was
further performed by an experienced pathologist using
standard hematoxylin and eosin staining and the staging
of NSCLC by a clinical oncologist according to the Inter-
national Association for the Study of Lung Cancer
(IASLC) TNM-classification. Clinicopathological charac-
teristics of the NSCLC patients were shown in Additional
file 1: Table S1. Adjacent tissue was located within 3 cm of
the edge of the tumor tissue. This study was approved by
the Research Ethnics Committee of Wenzhou Medical
University. 5′-azacytidine (AZA, Sigma-Aldrich, St Louis,
MO, USA) was dissolved in distilled water and kept at
-20 °C until used.
Cell proliferation assay (Cell Counting Kit-8)
Lung cancer cells transfected with pLVX-miR-193a or
pLVX-NC were seeded into 96-well plates (6.0 × 103
cells per well). Cell proliferation was assessed by Cell
Counting Kit-8 assay (Beyotime Institute of Biotech-
nology, Shanghai, China). Cells were added with 10 μl
CCK-8 and incubated for 2 h at 37 °C. The absorbance
of each well was read on a spectrophotometer at
450 nm. Three independent experiments were per-
formed in quintuplicate.
Plasmid construction
To construct the plasmid that expresses miR-193a in
mammalian cells, the primary sequence of has-pre-miR-
193a and its flanking regions were amplified by specific
primer pairs and then were cloned into lentivirus vector
pLVX-puro (Clontech, Palo Alto, USA). The whole coding
sequence (CDS) of WT1 isoforms (NM_000378) were
directly synthesized (Genewiz, Suzhou, China) and then
cloned into retrovirus pMSCV-puro vector (Clontech).
Human WT1 CDS including the predicted miR-193a
target sites was amplified by PCR and cloned into pMIR-
REPORT vector named as pMIR-WT1CDS (Ambion,
Dallas, USA). The mutation on miR-193a-binding sites in
human WT1 CDS was generated by the site-directed mu-
tagenesis kit (Agilent Technologies, Palo Alto, USA). All
the primer sequences were shown in Additional file 2:
Table S2. All of these constructs were confirmed by
sequencing.
Retrovirus production and cell transfection
HEK293T cells (4 × 106) were plated in 10 cm dish. After
24 h, LVX-puro-miR-193a and MSCV-puro-WT1 vectors
were cotransfected with packaging and envelope vectors
into HEK293T cells. Virus was harvested from the super-
natant at 48 h posttransfection, and was mixed with 8 μg/
ml polybrene (Sigma-Aldrich, St. Louis, USA) to increase
the infection efficiency. To select the cells stably expressing
miR-193a, 2 μg/ml puromycin (Medchemexpress,
Princeton, USA) was added into the supernatant for
1 week.
Luciferase activity
A549 cells were seeded in 24-well plates at a density
of 1.0 × 105 cells per well. After growth for 24 h, each
well was transiently cotransfected with 100 ng pMIR-
REPORT plasmid containing 10 ng internal control
vector pRL-SV40 (Promega, Madison, USA), wild-type
or mutant pMIR-WT1CDS, and 60 pmol scramble or
miR-193a mimics using Hiperfect transfection reagent
(Qiagen). Firefly and renilla luciferase activities were
measured in cell lysates after transfection for 24 h by
the Dual-Luciferase Reporter Assay System (Promega).
The value of relative luciferase activity indicates the
firefly luciferase activity normalized to that of renilla
for each assay.
RNA interference
Gene-specific short hairpin RNA (shRNA) for WT1 were
designed and cloned into pSIREN-RetroQ (Clontech)
retroviral vector. Control shRNA is a nonfunctional
construct provided from Clontech. The sequences of sh-
WT1 were indicated in Additional file 2: Table S2. These
shRNAs vectors or negative vector were co-transfected
with packaging plasmids Gap-pol and VSV-G into 293T
cells to produce retrovirus. Supernatants containing retro-
virus were collected at 48 h after transfection and were
used to infect lung cancer cells. Positive clones with stable
knockdown of WT1 were selected by 2 μg/ml puromycin
(Medchemexpress) for 1 week.
RNA extraction and stem-loop reverse transcription-
polymerase chain reaction
Total RNA was extracted using Trizol reagent (Invitro-
gen, Carlsbad, CA) following the procedure by some
slight modifications. The cells or tissues were incubated
for five min at room temperature after being lysed with
1 ml Trizol reagent. The lysates were vigorously mixed
with 300 μl chloroform and laid for 15 min at room
temperature. After centrifugation for 20 min at 4 °C,
500 μl isopropanol was applied to precipitate RNA in
the upper solution. Finally, RNA was dried and dissolved
with RNase-free water. Mature miR-193a and U6 snRNA
were reversely transcribed using stem-loop RT primer
with miscript II RT Kit (Qiagen, Valencia, USA). Real-
time PCR was performed using SYBR Green PCR
Master Mix (Qiagen) in an Applied Biosystems 7500
instrument. Expression data were uniformly normalized
to the internal control U6 and the relative expression
levels were evaluated using the 2-ΔΔCt method.
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Wound healing assay
Cells were pretreated with mitomycin (25 μg/ml,
Medchemexpress), seeded in six-well plates, and cultured
to confluence. Wounds of two-mm width were created
with a plastic scriber, followed with washing away the
floating cells with PBS. After incubation in a serum free
medium for 12 h, cultures were observed and photos were
taken under a microscope at 24 h.
Immunofluorescence staining
Lung cancer cells were plated on a glass slide and fixed
with 4 % formaldehyde for 30 min, followed with methyl
alcohol for 20 min. Slides were blocked with 5 % bovine
serum albumin for 2 h, and then were incubated for
overnight with primary antibody for WT1, E-cadherin,
Fibronectin, and Vimentin (Abcam, Cambridge, USA).
Slides were washed and then incubated with second
immunoglobulin-FITC or -PE antibody for 1 h and
counterstained for nuclear by DAPI (0.2 μg/mL) for
15 min. The staining was analyzed under a fluorescence
microscope (Olympus BX51, Tokyo, Japan) and Imstar
FISH Progress software to capture the pictures.
Immunohistochemistry analysis
Frozen section-based immunohistochemistry analysis
was performed to detect WT1 and E-cadherin expres-
sions in xenografts from nude mice and human lung
cancer tissues. Briefly, optimal cutting temperature-
entrapped specimens were sliced as 4 μm sections and
dried for 1 h at room temperature. The sections were
treated with 3 % H2O2 in methanol for 10 min at room
temperature to quench the endogenous peroxidase activ-
ity, followed by incubation with 5 % bovine serum albu-
min for 2 h at 37 °C to antagonize non-specific binding.
The slides were incubated with primary antibodies,
which were diluted with 1:100, for overnight, followed
with further incubation with horseradish peroxidase-
conjugated second antibody (Maixin, Fujian, China) at
room temperature for 30 min. The tissue sections were
immersed in 3.3′-diaminobenzidine and the reaction
was terminated when positive staining was present.
Subsequently, hematoxylin was used to counterstain the
sections for 10 min at room temperature. Following de-
hydration and mount, the sections were visualized. The
brown or sepia staining signal denotes positive regions.
Image-Pro Plus software (v5.0) was used to analyze aver-
age values of integrated optical density (IOD) from five
random fields per slide.
Western blot analysis
Proteins extracted from cultured cells or tissues were
quantitated by a protein assay (Beyotime, Shanghai,
China). Cell or tissue lysates were fractionated by sodium
dodecyl sulfate polyacrylamide gel electrophoresis and
then transferred to nitrocellulose membrane (Millipore,
Billerica, USA). Following blocking in PBS containing 5 %
fat-free milk, the nitrocellulose membrane was incubated
with primary antibodies against WT1, E-cadherin, Fibro-
nectin, and Vimentin (Abcam). Blots were stripped and
reprobed with β-actin antibody (Santa Cruz Biotechnol-
ogy, California, USA) as an internal control. After
overnight at 4 °C and then incubated with horseradish
peroxidase-conjugated anti-rabbit IgG for 1 h at room
temperature, the antigen–antibody immunoreactivity was
detected in a sensitive digital imaging equipment (Bio-
Rad, Richmond, USA) using a commercial ECL detection
kit (Millipore). All experiments were repeated three times
with the similar results.
Migration and invasion assay
The migration and invasive ability of the cells was inves-
tigated using Transwells (Corning Costar Corp, Bedford,
USA), which were put into 24-well plates. For migration
assay, 5 × 104 lung cancer cells were put into the upper
compartment. For invasion assay, 1 × 105 lung cancer
cells were put into the upper compartment per well with
the Matrigel-coated membrane (BD Biosciences, San
Jose, USA), which was diluted with serum-free culture
medium. In both assays, after 400 μl of RPMI 1640
containing 10 % fetal bovine serum was added to the
lower compartment, lung cancer cells were suspended in
200 μl RPMI 1640 containing 2 % fetal bovine serum
and were put into the upper compartment. After incuba-
tion for 48 h at 37 °C, the membrane inserts were
removed from the plate, and non-invading cells were
removed from the upper surface of the membrane. Cells
that moved to the bottom surface of the chamber were
fixed with 2 % paraformaldehyde for 20 min, and stained
with 0.1 % crystal violet for 30 min. Then, the cells were
imaged and counted in at least 10 random fields using a
CKX41 inverted microscope (Olympus, Tokyo, Japan).
The assays were conducted three independent times.
Methylation-specific polymerase chain reaction (MSP)
Genomic DNA was extracted from lung cancer cell
lines, lung cancer tissues, and adjacent non-tumor
tissues using DNA Purification Kit (Qiagen). Treatment
of DNA with bisulfite was performed by a commercially
available kit (Millipore). The methylation-specific poly-
merase chain reaction (MSP) for promoter of pre-miR-
193a was designed by MethPrimer software [27].
Tumorigenicity in nude mice
Male athymic nude mice were purchased from SLAC
(Shanghai SLAC Laboratory Animal, Shanghai, China).
Animal-related experiments were performed according
to the Guide for the Care and Use of Laboratory
Animals (National Institutes of Health Publications) and
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approved by the committee for humane treatment of
animals at Wenzhou Medical University Institutional
Guidelines. The animals were maintained under specific
pathogen free (SPF) conditions in the Animal Facility,
Wenzhou Medical University. To determine whether
miR-193a impacts tumorigenesis, 14 four-week-old mice
were randomly divided into two equal groups. A total of
1 × 107 viable A549-LVX-NC or A549-LVX-miR-193a
cells were trypsinized and resuspended with 200 μl ster-
ile 1× PBS and injected subcutaneously into right flank
of each nude mouse. Both the long and short diameters
of xenografts were measured using vernier calipers every
3 days after 2 weeks. All mice were sacrificed and the
tumors from each mouse were harvested and weighed
when the experiment was terminated at six weeks after
tumor cell inoculation. Tumor volumes were measured
using the equation V(mm3) = A × B2/2, where A is the
largest diameter and B is the perpendicular diameter.
Tumor lysates were prepared for western blot and
tumors were isolated for standard immunohistochemis-
try analysis.
Statistical analysis
Data are presented as mean ± standard error. Generally,
a two-tailed Student’s t-test was employed to evaluate
the differences between groups. Differences are consid-
ered as significant when the P value is <0.05. All statis-
tical analyses were performed with SPSS 22.0 software
(SPSS Inc., lllinois, USA).
Results
Downregulation of miR-193a in lung cancer tissues
To investigate the role of miR-193a in lung cancer cells,
the expression of miR-193a was detected in several lung
cancer cell lines and normal lung epithelial cell line
BEAS-2B. The level of miR-193a was significantly re-
duced in lung cancer cell lines compared with BEAS-2B
(Fig. 1a). To confirm the low expression of miR-193a in
lung cancer cells, the relative expression of miR-193a
was detected in lung cancer tissues and adjacent non-
tumor tissues. MiR-193a was downregulated in about
81 % of tumors (P < 0.01, 50 of 62 patients), with about
40 % reduction relative to their adjacent non-tumor
tissues by qRT-PCR (Fig. 1b). The relationship between
miR-193a expression levels and clinicopathological
characteristics of the NSCLC patients were indicated in
Additional file 1: Table S1. No statistically significant
correlations were observed between the miR-193a
expressions and age, gender, tumor size, or degree of
differentiation, respectively. However, the expression of
miR-193a was significantly decreased in lung cancer with
advanced stages (TNM III and IV) compared with early
stages (Stage I + II, Additional file 1: Table S1). Also,
miR-193a expression was reduced in lung cancer
patients with metastasis compared with those without
metastasis (Fig. 1c and Additional file 1: Table S1).
Gene silencing is often mediated by promoter hyper-
methylation in different kinds of cancers [28]. Using
MethPrimer software [27], we identified typical CpG
islands around the region encoding pre-miR-193a, sug-
gesting that miR-193a was likely regulated by DNA
methylation (Fig. 1d). To further determine whether the
CpG islands of pre-miR-193a were hypermethylated in a
tumor-specific manner, the methylation status of miR-
193a was analyzed by methylation-specific PCR (MSP)
in several lung cancer cell lines and BEAS-2B. Hyperme-
thylation of miR-193a was observed in seven lung cancer
cell lines (Fig. 1e). In contrast, a complete absence of
miR-193a methylation was found in BEAS-2B cells
(Fig. 1e). Furthermore, we investigated the status of
methylation in lung cancer tissues and adjacent non-
tumor tissues. Similarly, 23 of 27 DNA from lung cancer
tissues presented hypermethylation (Fig. 1f–h). However,
hypermethylation was only detected in 1 of 27 adjacent
non-tumor tissues (Fig. 1i–k). To further explore
whether DNA hypermethylation mediates the silencing
of miR-193a, A5459 and H1299 cells were treated with
DNA methyltransferase inhibitor 5′-azacytidine (AZA)
and the levels of miR-193a was measured. AZA
increased miR-193a expression in a time-dependent
manner (Fig. 1l).
Ectopic expression of miR-193a inhibits metastasis in lung
cancer cells
The reduced expression of miR-193a prompted us to in-
vestigate the biological role of miR-193a in lung cancer.
Migration and invasion were evaluated in A549 and
H1299 cells transfected with lentivirus vector LVX-NC
or LVX-miR-193a. The relative expressions of miR-193a
were elevated by 93- and 102-fold in LVX-miR-193a-
transfected cells compared with normal control in A549
and H1299 cells (data not shown), respectively. MiR-
193a reduced the migration (Fig. 2a) and invasion
(Fig. 2b) in A549 and H1299 cells compared with nega-
tive control. Meanwhile, overexpression of miR-193a sig-
nificantly decreased the wound healing activity in A549
(Fig. 2c) and H1299 cells (Fig. 2d). Further, overexpres-
sion of miR-193a decreased the colony formation
(Fig. 2e) and suppressed cell proliferation (Fig. 2f ).
MiR-193a directly targets WT1 and indirectly modulates
E-cadherin
To determine potential target genes by miR-193a, sev-
eral miRNAs predicting software including miRwalk,
TargetScan, and PicTar were used to predict possible tar-
get genes. MiR-193a has an ability to bind CDS of WT1
(Fig. 3a). CDS of WT1 including putative miR-193a-
binding sites was subcloned into pMIR vector to
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produce wide-type vector pMIR-WT1CDS and mutation
vector pMIR-WT1CDS(Mut) (Fig. 3a). These vectors
were co-transfected together with miR-193a mimics or
its negative control into A549 cells. Overexpression of
miR-193a decreased the luciferase activities by approxi-
mately 40 %, which were almost abolished by the
mutation in putative miR-193a-binding sites (Fig. 3b). Fur-
thermore, miR-193a minics decreased the protein expres-
sion of WT1 in cells transfected with pMIR-WT1CDS
(Mut) (Fig. 3c, Left). However, miR-193a minics failed to
decrease WT1 expression in cells transfected with pMIR-
WT1CDS (Fig. 3c, Right). We speculated that pMIR-
WT1CDS binds miR-193a minics and consequently
prevents miR-193a-induced decrease of WT1. To further
explore the role of miR-193a in lung cancer cells, A549
and H1299 cells were transfected with lentivirus vector
LVX-miR-193a or negative control. Overexpression of
miR-193a significantly decreased the protein levels of
WT1, but increased the expression of the epithelial
marker E-cadherin (Fig. 3d), which was reported to be
negatively regulated by WT1 in NSCLC [15]. Immuno-
fluorescent analysis also showed that the expression of
WT1 was decreased but E-cadherin was increased in miR-
193a-transfected cells compared with negative control
(Fig. 3e and Additional file 3: Figure S1A).
Because previous data showed that WT1 was increased
in hematological malignancies and multiple types of can-
cers [12, 29], we then determined whether the expression
of WT1 was increased in lung cancer tissues. We investi-
gated 62 pairs of NSCLC (Additional file 1: Table S1) and
corresponding adjacent specimens using qRT-PCR.
Consistent with previous report [30], the level of WT1 in
lung cancer tissues was higher than that in paired adjacent
non-cancer ones (Fig. 3f). We further analyzed the
Fig. 1 miR-193a was downregulated in lung cancer cells due to DNA hypermethylation. a The expression of miR-193a was detected in several
lung cancer cell lines and normal lung epithelial cell line BEAS-2B by qRT-PCR. b The expression of miR-193a was measured in lung cancer tissues
and adjacent non-tumor tissues. n = 62. c The expression of miR-193a was detected in lung cancer tissues with metastasis (n = 24) or without
metastasis (n= 38). d CpG islands around the region encoding pre-miR-193a were analyzed by MethPrimer software. e The methylation status of miR-193a
was analyzed by MSP in several lung cancer cell lines and BEAS-2B. Ma: DNA marker; B: Blank; P: positive control of methylated DNA. Bands of ‘M’ or ‘U’ are
PCR products from methylation-specific or unmethylation-specific primers, respectively. f–k The methylation status of miR-193a was analyzed by MSP in 27
lung cancer tissues (f–h) and 27 adjacent non-tumor tissues (i–k). l The expression of miR-193a was detected in A549 and H1299 cells treated with 5 μM
AZA for 3 and 5 days. *P< 0.01 versus untreated cells
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relationship between WT1 and miR-193a expressions.
Importantly, a significant inverse correlation between
miR-193a and WT1 mRNA expressions was found in lung
cancer tissues (Fig. 3g). Finally, we confirmed the overex-
pression of WT1 by IHC in 20 lung cancer tissues (11
adenocarcinoma and 9 squamous cell carcinomas). The
average value of integrated optical density (IOD) was
higher in lung cancer tissues compared with paired adja-
cent non-cancer ones (Fig. 3h and i).
Knockdown of WT1 inhibits metastasis
Having shown that miR-193a negatively regulates WT1
expression and inhibits metastasis, we directly address the
role of WT1 downregulation in the anti-metastasis activ-
ity. To determine whether WT1 knockdown resembles
the effects of miR-193a in our experimental model, lung
cancer cells were transfected with specific shRNA for
WT1 (sh-WT1). As shown in Fig. 4a and b, the mRNA
and protein levels of WT1 were decreased by sh-WT1.
Accordingly, knockdown of WT1 reduced the migration
(Fig. 4c) and invasion (Fig. 4d) in lung cancer cells. Fur-
thermore, WT1 knockdown reduced colony formation
(Fig. 4e) and decreased cell growth in A549 (Fig. 4f) and
H1299 cells (Fig. 4g).
Ectopic overexpression of WT1 partially reverses miR-
193a-induced inhibition of metastasis
Because miR-193a inhibited metastasis via targeting
WT1 protein, which acts as an oncogene in multiple
types of cancers including lung cancer, we are interested
in examining whether WT1 counteracts miR-193a-
induced anti-metastasis. Migration and invasion were
measured in miR-193a-overexpressed A549 and H1299
cells, which were transfected with MSCV-NC or MSCV-
WT1. As shown in Fig. 5a, miR-193a-induced inhibition
of WT1 was prevented by transfection of MSCV-WT1
compared with negative control. Correspondingly, over-
expression of WT1 partially reversed the anti-migration
(Fig. 5b) and anti-invasion (Fig. 5c) induced by miR-
193a. Further, overexpression of WT1 partially pre-
vented miR-193a-induced growth inhibition (Fig. 5d and
e). Finally, migration and invasion were measured in
miR-193a-overexpressed A549 cells transfected with
MSCV-NC or MSCV-WT1 CDS (Mut). As shown in
Fig. 2 The anti-metastasis activity of miR-193a in lung cancer cells. a and b Transwell migration (a) and invasion (b) assays were performed in A549
and H1299 cells transfected with lentivirus LVX-miR-193a or negative control LVX-NC. *P < 0.01 versus NC. c and d Wound healing assay was measured
in A549 (c) and H1299 cells (d), which were transfected with LVX-miR-193a or LVX-NC. *P < 0.01 versus NC. e Colony formation was performed by
methylene blue staining in A549 and H1299 cells transfected with LVX-miR-193a or LVX-NC. *P < 0.01 versus NC. f Cell proliferation was detected by
CCK-8 assay in A549 and H1299 cells transfected with LVX-miR-193a or LVX-NC for 24, 48, and 72 h. Scale bar = 50 μm. The results are representative of
at least three independent experiments. Statistical analysis was performed using Student’s t-test
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Additional file 4: Figure S2A-C, overexpression of WT1
CDS (Mut) did not prevent the anti-migration and anti-
invasion induced by miR-193a.
TGF-β1-induced EMT is attenuated by the overexpression
of miR-193a
The observation that overexpression of miR-193a inhibited
metastasis through WT1-E-cadherin axis urged us to inves-
tigate whether miR-193a is mediated in the EMT of lung
cancer cells. TGF-β1 promotes tumor progression through
enhancing migration, invasion, and proliferation, in part by
its ability to induce EMT [31]. Decreased expression of the
epithelial marker E-cadherin and increased expression of
the mesenchymal markers fibronectin and vimentin were
found in A549 and H1299 cells treated with 10 ng/ml
TGF-β1 for 3 days by immunofluorescence (Fig. 6a and
Additional file 5: Figure S3A), morphology (Fig. 6b), and
western blot (Fig. 6c). A549 and H1299 cells displayed a
Fig. 3 miR-193a modulates E-cadherin expression through targeting WT1. a Schematic of putative binding sites for miR-193a in WT1 CDS. b A549
cells were transfected with wide-type pMIR-WT1CDS, pMIR-WT1CDS (Mut), pMIR-NC, and the pRL-SV40 containing Renilla luciferase gene for 24 h,
followed by the transfection with miR-193a mimic or Scramble for another 24 h. Firefly and Renilla luciferase activities were both detected and
histograms showed the Firefly luciferase activities normalized to Renilla luciferase activities. *P < 0.01 versus Scramble. c Western blot for WT1
was performed in lysates from A549 cells, which were treated as Fig. 3b. d WT1 and E-cadherin expressions were performed in A549 and H1299
cells transfected with lentivirus LVX-miR-193a or LVX-NC. e Immunofluorescence (IF) staining assay for WT1 and E-cadherin was analyzed in A549 cells
transfected with LVX-miR-193a or LVX-NC. Scale bar = 50 μm. f WT1 expression was measured in lung cancer tissues and adjacent non-tumor tissues
by qRT-PCR. n= 62. g The plotting of miR-193a versus WT1 expression showed an inverse correlation between them. A statistically significant correlation
between miR-193a versus WT1 expression was observed by Pearson’s method. n= 62. h A representative picture of immunohistochemical staining of WT1
in an adenocarcinoma (left) and adjacent non-cancer specimen (right). i Average value of integrated optical density (IOD) was evaluated by analyzing six
fields per slide and recorded in the histogram. n= 20
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spindle-shape and fibroblast-like morphology in the
presence of TGF-β1 compared with a classic epithelial
morphology in the absence of TGF-β1 (Fig. 6b). All these
data suggest that TGF-β1 could successfully induce EMT
in A549 and H1299 cells. To further determine the role of
miR-193a in the TGF-β1-induced EMT, A549 and H1299
cells transfected with LVX-miR-193a or negative control
were treated with TGF-β1 for 3 days. TGF-β1-induced
EMT was partially prevented by the overexpression of miR-
193a (Fig. 6d and e). Because miR-193a expression was
more decreased in lung cancer cells with greater migration
and invasion abilities, we speculated that TGF-β1 inhibited
the expression of miR-193a. As expected, TGF-β1 reduced
the expression of miR-193a by 30 %–50 % (Fig. 6f) and sub-
sequently increased the expression of WT1 in A549 and
H1299 cells (Fig. 6g).
MiR-193a reduces tumorigenicity in a xenograft mouse
model
Finally, we determined whether overexpression of miR-
193a could reduce the tumorigenicity in a xenograft
model. Tumors in mice inoculated with LVX-miR-193a
were significantly smaller than those in control mice
(Fig. 7a). Furthermore, tumor growth was significantly
reduced in mice inoculated with LVX-miR-193a (Fig. 7b).
Similarly, the average tumor volume and average tumor
weight in mice inoculated with LVX-miR-193a was
reduced by 47.2 % (Fig. 7c) and 54.9 % (Fig. 7d) com-
pared with negative control, respectively. Consistent
with the results from cell lines, the protein levels of
WT1 were significantly decreased but E-cadherin ex-
pressions were increased in two tumors obtained from
miR-193a-overexpressed mice in comparison with
control mice (Fig. 7e). Finally, IHC staining indicated
that the expression of WT1 was decreased while E-
cadherin was increased in tumor xenograft from mice
inoculated with A549-miR-193a than that inoculated
with A549-miR-NC (Fig. 7f ).
Discussion
MiRNAs have critical roles in carcinogenesis and metas-
tasis. Identification of tumor-related miRNAs and their
direct target genes is important for understanding the
biological significance of miRNAs in tumorigenesis. In
this study, we investigated an anti-metastasis role of
miR-193a in NSCLC. Our results indicate that decreased
expression of miR-193a contributes to proliferation,
metastasis, and TGF-β-induced EMT through WT1-E-
Fig. 4 Knockdown of WT1 resembles the anti-metastasis activity by miR-193a. A549 and H1299 cells were transfected with specific shRNA for
WT1 or nonspecific shRNA (sh-NC). a and b WT1 protein and mRNA levels were detected in A549 and H1299 cells transfected with sh-NC or sh-
WT1. *P < 0.01 versus sh-NC. c and d Transwell migration (c) and invasion (d) assays were performed in A549 and H1299 cells transfected with sh-
NC or sh-WT1. Scale bar = 50 μm. *P < 0.01 versus sh-NC. e Colony formation was performed by methylene blue staining in A549 and H1299 cells
transfected with sh-NC or sh-WT1. *P < 0.01 versus sh-NC. f and g Cell proliferation was detected by CCK-8 assay in A549 (f) and H1299 (g) cells
transfected with sh-NC or sh-WT1 for 24, 48, and 72 h. *P < 0.01 versus sh-NC
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cadherin pathway. Consistently, ectopic overexpression
of miR-193a inhibits metastasis and the EMT-like
conversion in NSCLC. Intriguingly, miR-193a expression
is decreased in TGF-β-induced EMT, suggesting that miR-
193a-WT1-E-cadherin pathway was mediated in TGF-β-
induced EMT. Therefore, our results suggest that miR-
193a exerts tumor-suppressive effects through WT1-E-
cadherin pathway.
Dysregulation of miRNAs is frequently observed in
various kinds of cancer and miRNAs can function as on-
cogenes or tumor suppressive genes. In our study, the
levels of miR-193a were lower in lung cancer tissues
than those in normal noncancerous tissues, suggesting
that miR-193a might be involved in the pathogenesis of
lung cancer as a tumor suppressor. Further, lower
expression of miR-193a was related with greater migra-
tion and invasion. Indeed, many studies have indicated
that miR-193a was down-regulated in various types of
cancers [32–34]. Consistently, miR-193a-3p, the another
product of pre-miR-193a, was also downregulated in
lung cancer [25, 34]. DNA methylation has been
suggested as one of the mechanisms which might be
associated with miRNA silencing. Our studies also
indicate that hypermethylation of miR-193a is frequently
occurred in lung cancer cell lines and lung cancer tissues
but not in adjacent non-tumor tissues. These observa-
tions are compatible with the work by Heller et al. that
miR-193a was silenced by DNA hypermethylation
through genome-wide miRNA expression profiling [35].
TGF-β induces the repression of E-cadherin through
several well recognized transcriptional repressors, such as
Snail, Slug, Twist, Zeb 1/2, and E47 [36]. Here, we report
that miR-193a-mediated pathway may take part in TGF-
β-induced inhibition of E-cadherin (Additional file 6:
Figure S4A). The further decrease of miR-193a by TGF-β
loses the ability of suppressing WT1 and finally enhances
the expression of WT1, which leads to the decreased
expression of E-cadherin (Additional file 6: Figure S4B).
Several reports also indicated that miRNAs modulated
EMT through different mechanisms [37]. For example,
TGF-β-induced inhibition of miR-200 led to the increased
expression of Zeb, which finally decreased the expression
of E-cadherin in breast cancer cells [38, 39]. TGF-β in-
creased the expression of miR-181a to promote EMT-like
change in cirrhosis and hepatocellular cancer [40]. There-
fore, TGF-β-miR-193a-E-cadherin pathway complements
Fig. 5 miR-193a-induced inhibition of metastasis is partly prevented by ectopic overexpression of WT1. a Western blot was analyzed in A549 and
H1299 cells transfected with LVX-miR-193a and retrovirus MSCV-NC or MSCV-WT1. b and c Transwell migration (b) and invasion (c) assays were
performed in these cells. d and e Cell proliferation was detected by CCK-8 assay in A549 (d) and H1299 (e) cells, which were transfected with
LVX-miR-193a and retrovirus MSCV-NC or MSCV-WT1 for 24, 48, and 72 h. *P < 0.01 compared with MSCV-NC
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the routine regulatory net in EMT. However, further stud-
ies are needed to determine the underlying mechanism by
which miR-193a is decreased by TGF-β.
In most normal cells, E-cadherin binds β-catenin to
maintain normal cell structure. This complex forms a
powerful molecular barrier that prevents the prolifera-
tion, invasion, and metastasis. During EMT process, the
loss of E-cadherin leads to the damaged junctions and
decreased contact inhibition. Consequently, β-catenin
enters the nucleus and activates Wnt/β-catenin signaling
Fig. 6 Overexpression of miR-193a partly reverses TGF-β1-induced EMT. A549 and H1299 cells were treated with 10 ng/ml TGF-β1 for 3 days. a
Immunofluorescence staining was performed for epithelial marker E-cadherin and the mesenchymal markers fibronectin and vimentin in A549
cells. b Morphologic changes associated with EMT at 3 days were shown in the phase contrast images. c Western blot for E-cadherin,
fibronectin, and vimentin in A549 and H1299 cells treated with TGF-β1 for 3 days. d and e A549 and H1299 cells were transfected with
LVX-NC or LVX-miR-193a, followed with treatment with TGF-β1 for 3 days. Immunofluorescence staining assay was performed for E-
cadherin in these cells. f and g The expressions of miR-193a (f) and WT1 (g) were measured in A549 and H1299 cells treated with TGF-β1
for 3 days by qRT-PCR and western blot, respectively
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to induce the expression of transcript factors such as
Snails and Zebs, which finally inhibit the expression of
E-cadherin encoding gene CDH1 [41]. Therefore, the
loss of E-cadherin expression is considered as the
important step for EMT process. In most fully differenti-
ated cancer tissues, E-cadherin is highly expressed and
predicts better outcome. However, some reports indicate
that many invasive and metastatic cancers maintain high
expression of E-cadherin [42]. For example, overexpres-
sion of E-cadherin in human breast cancer cell line
MDA-MB-435 does not inhibit motility and metastasis
[43]. Another study indicates that E-cadherin expression
is similar in breast ductal carcinoma and in normal
glands [42]. High expression of E-cadherin is discovered
in malignant ovarian carcinomas and promotes the
malignant transformation of ovarian epithelial cells [44].
Similarly, high expression of E-caderin is positively
correlated with the invasive growth and infiltration of
prostate cancer cells [45]. These reports indicate that E-
cadherin expression is not associated with metastatic
status or mesenchymal phenotype. Also, this observa-
tions indicate that E-cadherin don’t prevent the expan-
sion of carcinoma cells into surrounding tissues. This
discrepancy might be due to the complex role of E-
cadherin in metastasis or the different responses of cells
which are treated with stimuli. However, most studies
indicate that the reduction of E-cadherin expression in
lung cancer cells is associated with low tumor differenti-
ation, high metastasis, and poor outcome [46, 47]. Our
data affirm these results and indicate a new TGF-β-miR-
193a-E-cadherin pathway to promote TGF-β-induced
EMT in lung cancer.
MiRNAs have been implied to play crucial roles of
EMT in NSCLC. In addition to miR-193a, several other
Fig. 7 The anti-tumor effects of miR-193a in tumor xenograft. About 1 × 107 viable A549 cells transfected with pLVX-miR-193a (A549-miR-
193a) or pLVX-miR-NC (A549-miR-NC) were subcutaneously injected into right flank of each nude mouse. n = 7. a A photograph of tumors
from mice inoculated with A549-miR-193a or A549-miR-NC. b Volumes of all tumors were detected every 3 days after 2 weeks. c Volumes
of all tumors were measured when the experiment was terminated at six weeks after tumor cell inoculation. d Net weights of all tumors
were measured at the termination of the experiment. e The protein levels of WT1 and E-cadherin were detected in two tumor lysates from
mice inoculated with A549-miR-193a or A549-miR-NC. f IHC staining of WT1 and E-cadherin was done in tumor xenografts from mice
inoculated with A549-miR-193a or A549-miR-NC cells. Scale bar = 50 μm
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miRNAs are mediated in the EMT of NSCLC. For
example, miR-149 expression was downregulated in lung
cancer and was inversely correlated with invasive
capability in NSCLC. Furthermore, miR-149 inhibited
EMT via directly targeting Forkhead box M1 (FOXM1),
which was involved in the TGF-β-induced EMT [48].
The expression of miR-132 was significantly decreased
in NSCLC cell lines and clinical NSCLC cancer tissues.
Mechanistically, overexpression of miR-132 suppressed
EMT process via inhibiting ZEB2-E-cadherin signaling
[49]. MiR-134/487b/655 cluster, which was increased by
TGF-β, contributed to TGF-β-induced EMT through the
loss of PTEN stability [50]. Our finding that miR-193a
inhibits TGF-β-induced EMT through WT1-E-Cadherin
axis augments the role of miRNAs in EMT of NSCLC.
Therefore, completely investigating the whole miRNAs
mediated in the process of EMT might facilitate the
knowledge of pathogenesis in NSCLC.
A single miRNA can target multiple genes, whereas
multiple miRNAs can target a single gene. Thus, miR-
193a might have multiple different mRNA targets other
than WT1, and these additional targets may also play
important roles in carcinogenesis. In addition to WT1,
miR-193a targeted several important oncogene, such as
Yin Yang1 (YY1) [33], phosphoinositide-3-kinase regula-
tory subunit (3PIK3R3), and the mammalian target of
rapamycin (mTOR) [34]. Similarly, besides miR-193a,
miR-125a was identified to suppress WT1 expression via
binding 3′UTR of WT1 in myeloid leukemia cells [51].
Our previous data also indicated that miR-15a/16-1 inhib-
ited the expression of WT1 probably through an indirect
mechanism in leukemic cells [52]. Thus, elucidating the
complex regulatory net of WT1 by miRNAs may shed
light on the high expression of WT1 in cancer cells.
Most of studies demonstrate that WT1 is overexpressed
in lung cancer cells and WT1 acts as oncogene to promote
proliferation and metastasis [12, 30]. For example, Xu et al.
reported that WT1 facilitated NSCLC cell proliferation by
up-regulating Cyclin D1 and p-pRb expressions [12]. Wang
et al. demonstrated that isoform C of WT1 was overex-
pressed in lung cancer and WT1 facilitated the carcinogen-
esis of lung cancer via regulating PI3K/AKT signaling
pathway [53]. However, whether the higher expression of
WT1 predicted poor metastasis in lung cancer remains
controversial. Hayashi S et al. reported that low expression
of WT1 was a negative prognostic factor in NSCLC tumors
and was also associated with lymph node metastasis [54].
In addition, Moriya and his colleagues indicated that high
level of WT1 was associated with the suppression of lymph
node metastasis in patients with human lung squamous cell
carcinoma (SCC) [55]. The possible reason for this discrep-
ancy is likely due to the complex isoforms of WT1 [14]. At
least eight major isoforms of WT1 were isolated from a
cDNA library in lung cancer tissues [55]. However, the role
of single WT1 isoform in lung cancer is large unknown.
Further studies are thus needed to resolve this discrepancy.
Inhibition of WT1 in solid cancers and hematological
malignancies demonstrates potential anti-tumor activities.
WT1 knockdown by antisense oligomers [56], ribozyme
[57], or PEI- RNAi [58] suppresses cell proliferation and
induces apoptosis, suggesting that removal of WT1 might
has anti-cancer effect in multiple types of cancers. Add-
itionally, WT1 peptide-based immunotherapy shows good
clinical responses, such as reduction in tumor sizes,
demonstrating that WT1 vaccination should be a promis-
ing treatment for patients with lung cancer, breast cancer,
and leukemia [59]. Therefore, inhibiting or degrading WT1
protein might contribute to the clinical treatment for
WT1-overexpressed lung cancer patients.
Conclusions
In summary, we explore the role of miR-193a-WT1-E-cad-
herin axis in the metastasis and EMT in NSCLC. MiR-193a
expression is decreased due to DNA hypermethylation in
NSCLC specimens. Restoration of miR-193a inhibits migra-
tion, invasion, and TGF-β1-induced EMT through modu-
lating WT1-E-cadherin axis. Furthermore, overexpression
of WT1 partially prevents miR-193a-induced inhibition of
migration and invasion, suggesting that WT1 plays an
important role in the anti-metastasis by miR-193a. Thus,
restoring the expression of miR-193a or decreasing the
expression of WT1 might provide alternative therapeutic
strategy for NSCLC patients.
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